|  |  |
| --- | --- |
|  | **NHS Prescription Services**Bridge House152 Pilgrim StreetNewcastle upon TyneNE1 6SN0845 850 0001 Email:nhsbsa.prescriptionservices@nhsbsa.nhs.ukWebsite:[www.nhsbsa.nhs.uk](http://www.nhsbsa.nhs.uk)  15 Jan 2024 |
|  |

VERSION 1.2.0

Dear dm+d User,

[**VMP ‘<Drug Form>’ coded attribute in dm+d – Advanced notice of Phase 2 changes**](https://nhsengland.kahootz.com/t_c_home/viewBlogArticle?articleID=982361&nextURL=%2Ft_c_home%2FviewBlog%3Fblogid%3D50136)

Following on from the Phase 1 drug form changes which appeared in the dm+d data on Monday 20 November 2023, we are providing **advanced notification** of the proposed dates for Phase 2 drug form changes.

The new Phase 2 drug forms were released in the TRUD extract Monday 15 January 2024, however these descriptions and codes will not be attached to VMPs until the dates confirmed (see below).

Updates to the following drug forms are being planned to take place in the dm+d data:

|  |  |
| --- | --- |
| **Dates** | **Phase 2 Drug Form Changes** |
| **Monday 29 January 2024** | * Implant,
* **Implantation suspension**
* **Irrigation**
* **Irrigation solution**
 |
| **Monday 12 February 2024**AND**Monday 19 February 2024** | * **Liquid**\*
* **Powder\***

***\*Excluding oral and gastroenteral powders and liquids*** |
| **Monday 11 March 2024**AND **Monday 18 March 2024**AND **Monday 25 March 2024** | * **Oral and gastroenteral powders**
* **Oral and gastroenteral liquids**
 |

More detailed information, including what new updated drugs forms will be available, are published on the webpage [Updating the NHS dm+d ‘<DRUG\_FORM>’ coded attribute within the Virtual Medicinal Product concept class - NHS Digital](https://digital.nhs.uk/services/terminology-and-classifications/uk-medicines-terminology-futures/changes-to-digital-terminologies/updating-the-nhs-dm-d-drug_form-coded-attribute-within-the-vmp-concept-class)

Information advising how technical queries might be written to identify VMP Drug Form changes from either TRUD or NHSE Terminology Server can be found here: [Identifying updates to the VMP <DRUG\_FORM> code attribute in Dictionary of medicines and devices (dm+d) - NHS Digital](https://digital.nhs.uk/services/terminology-and-classifications/uk-medicines-terminology-futures/changes-to-digital-terminologies/identifying-updates-to-the-vmp-drug_form-code-attribute-in-dm-d)

**dm+d Editorial Policy Update**

An updated version of the dm+d Editorial Policy will be in the public domain by Monday 15th January close of business.

For more information please see the dm+d Resources section on the following webpage: [Dictionary of medicines and devices (dm+d) | NHSBSA](https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/dictionary-medicines-and-devices-dmd)

**Advanced Notice: Rivaroxaban (Xarelto® 1mg/ml granules for oral suspension) Update - dm+d VMPP/AMPP Pack Sizes to be Updated to Reflect the Volumes of Water added for Reconstitution**

A dm+d issue has been raised regarding concerns that the volumes listed in the Drug Tariff and dm+d for Xarelto 1mg/ml granules for oral suspension do not reflect the actual usable volumes of the suspension after reconstitution which are not defined in the SmPC and packaging.

The dm+d Content Committee discussed this at length in a recent meeting. The Committee unanimously agreed that, for this product, the VMPPs/AMPPs will be updated to be based on the volumes of water added for reconstitution. This is the most pragmatic way forwards in the absence of final reconstituted volumes being categorically published in the SmPC.

Similarly, to plans previously communicated via this TRUD platform in June 2023, we will shortly be updating the pack sizes in dm+d to reflect the volumes of water added for reconstitution (rather than the bottle sizes) as follows:

**VMP**: Rivaroxaban 1mg/ml granules for oral suspension sugar free

|  |  |
| --- | --- |
| **Pack size concepts to be made INVALID** | **REPLACEMENT pack size concepts** |
| VMPP: 100ml (bottle size) | VMPP: 50ml (volume of water added for reconstitution) |
| VMPP: 250ml (bottle size) | VMPP: 100ml (volume of water added for reconstitution) |

**AMP**: Xarelto 1mg/ml granules for oral suspension (Bayer Plc)

|  |  |
| --- | --- |
| **Pack size concepts to be made INVALID** | **REPLACEMENT pack size concepts** |
| AMPP: 100ml (bottle size) | AMPP: 50ml (volume of water added for reconstitution) |
| AMPP 250ml (bottle size) | AMPP 100ml (volume of water added for reconstitution) |

Note – the larger bottle size allows sufficient space for mixing the granules and water.

**Part VIIIA of the NHS England and Wales Drug Tariff** also includes an entry that refers to the 250ml pack size and this will similarly be updated from 250ml to 100ml.

**Clinical system suppliers should** update their systems in a timely manner and support their users. Please be mindful that there might be a time lag between prescribing and dispensing system updates. Also, if there is any confusion for a few weeks after the update, dispensers and prescribers may need to link in with each other to ensure that prescriptions are in line with and reflect the **REPLACEMENT pack size concepts** in the tables above.

Should you have any further enquiries, please email dmdenquiries@nhsbsa.nhs.uk

**Enterococcus faecalis Ingredient Update**

Generic Uromune (MV140) perlingual spray with four “active” ingredients has recently been authored in dm+d.

In the process of updating the Enterococcus faecalis ingredient description with the word ‘inactivated’, the Enterococcus faecalis ingredient description linked to core SNOMED 1187454003 was edited erroneously.

We have now removed the word inactivated from this description, authored the addition of a new ingredient description to dm+d of Enterococcus faecalis Inactivated with a UK extension SNOMED code: 42542711000001105 and updated the Generic Uromune (MV140) perlingual spray profile as appropriate.

Apologies for any inconvenience caused.

**NHS TRUD Platform**

For Week 51 **Release 12.2.1** is **identical to release 12.2.0**. **It has been re-released to align the release numbers following an update to the supplementary SNOMED history extract**. For further information, please see the following TRUD platform notes below:

**NHSBSA dm+d**

Release 12.2.1

Week 51.

The SNOMED history extract for release 12.2.0 picked up some SNOMED codes that started on Friday, 15 December 2023. These have been removed from [NHSBSA dm+d supplementary](https://isd.digital.nhs.uk/trud/users/guest/filters/0/categories/6/items/25/releases) release 12.2.1 to realign that file with data from Thursday, 14 December 2023.

This release is identical to release 12.2.0, but was re-released to align the release numbers.

Released on 19 December 2023.

**NHSBSA dm+d supplementary**

Release 12.2.1

Week 51.

The SNOMED history extract for release 12.2.0 picked up some SNOMED codes that started on Friday, 15 December 2023. These have been removed to realign this file with data from Thursday, 14 December 2023.

This release is otherwise identical to release 12.2.0.

Released on 19 December 2023

**SNOMED International consultation on the inactivation of Role Groupers in Substance and Medicinal Product Hierarchies**

For your information, please find links below to the briefing paper from SNOMED International (with accompanying documentation outlining the concepts impacted by these proposals) regarding the consultation on the inactivation of Role Groupers in Substance and Medicinal Product Hierarchies in SNOMED CT content:

* [20231103 BN Role Grouper Consultation.pdf](https://nhsengland.kahootz.com/gf2.ti/f/762498/186840069.2/PDF/-/20231103%20BN%20Role%20Grouper%20Consultation.pdf)
* [Medicinal Product therapeutic role groupers.xlsx](https://nhsengland.kahootz.com/gf2.ti/f/762498/186840133.1/XLSX/-/Medicinal%20Product%20therapeutic%20role%20groupers.xlsx)
* [Concepts Defined Using Substance Role Grouper November 2023.xlsx](https://nhsengland.kahootz.com/gf2.ti/f/762498/186840101.1/XLSX/-/ConceptsDefinedUsingSubstanceRoleGrouper_November2023%20_2_.xlsx)
* [Substance Role Groupers November 2023.xlsx](https://nhsengland.kahootz.com/gf2.ti/f/762498/186840037.1/XLSX/-/SubstanceRoleGroupers_November2023.xlsx)
* [SNOMED CT Concepts and Refset Membership.xlsx](https://nhsengland.kahootz.com/gf2.ti/f/762498/190099909.1/XLSX/-/SNOMED%20Concepts%20and%20Refset%20Membership.xlsx)

Please provide your feedback to the 5 questions within the **Member/user requirements**section (bottom of page 3 in the SNOMED International Briefing Note) to information.standards@nhs.net by 31 January 2024.

Responses will be collated and submitted to SNOMED International at the close of play on 31 January 2024.

If you have any questions, please email information.standards@nhs.net

**Product Pack Barcode**

On the NHSBSA dm+d browser under the AMPP level there has been a field visible entitled Product Pack Barcode.

Barcode images are not something the NHSBSA is able to reliably capture currently, and therefore this field will be removed from the NHSBSA dm+d browser imminently.

Apologies for any inconvenience caused.

**Monthly dm+d Supplier Workshop**

NHS England hosts a monthly workshop for IT system suppliers to discuss dm+d content and implementation queries.  It is an opportunity to speak with colleagues from NHS England and the NHSBSA who manage the terminology.

If you are a system supplier who is interested in joining the group, please contact medicinestandards@nhs.net for more information.

**DHSC require these concepts to be made available and visible (similar to licensed medicines) in prescribing and dispensing systems for the time being.**

|  |
| --- |
| **Specials/Imports added at request of DHSC to mitigate shortages in the supply chain** |
| **AMP Name** | **AMP SNOMED Code** | **Import/Special** | **dm+d extract date** |
| Desmopressin 150micrograms/dose nasal spray | 38955011000001100 | Imported  | 14/09/2020 |
| Desmopressin 150micrograms/dose nasal spray | 38996011000001101 | Special Order | 21/09/2020 |
| Capsaicin 0.025% cream | 41539411000001105 | Imported |  27/03/2023 |
| Capsaicin 0.075% cream | 41540711000001105 | Imported |  27/03/2023 |
| Imiquimod 5% cream 250mg sachets | 41526711000001106 | Imported |  14/08/2023 |
| Pethidine 50mg tablets | 42161611000001107 | Imported (United States) |  14/08/2023 |
| Permethrin 5% cream | 42243511000001101 | Imported |  18/09/2023 |
| Vyvanse 30mg capsules | 42409311000001100 | Imported |  13/11/2023 |
| Vyvanse 40mg capsules | 42409611000001105 | Imported |  13/11/2023 |
| Vyvanse 50mg capsules | 42409811000001109 | Imported |  13/11/2023 |
| Vyvanse 70mg capsules | 42410011000001109 | Imported |  13/11/2023 |
| Lisdexamfetamine 30mg capsules | 42415211000001108 | Imported |  20/11/2023 |
| Lisdexamfetamine 40mg capsules | 42415411000001107 | Imported |  20/11/2023 |
| Lisdexamfetamine 50mg capsules | 42415611000001105 | Imported |  20/11/2023 |
| Lisdexamfetamine 70mg capsules | 42415811000001109 | Imported |  20/11/2023 |
| Bisacodyl 5mg suppositories | 42439811000001104 | Special Order |  27/11/2023 |
| Bumetanide 1mg tablets | 42440311000001100 | Imported |  27/11/2023 |
| Bumetanide 5mg tablets | 42440611000001105 | Imported |  27/11/2023 |
| Co-trimoxazole 40mg/200mg/5ml oral suspension sugar free | 42440811000001109 | Imported |  27/11/2023 |
| Disopyramide 250mg modified-release tablets | 42441311000001105 | Imported |  27/11/2023 |
| Griseofulvin 125mg tablets | 42441511000001104 | Imported (United States) |  27/11/2023 |
| Griseofulvin 500mg tablets | 42441811000001101 | Imported (United States) |  27/11/2023 |
| Lamotrigine 5mg dispersible tablets sugar free | 41526311000001107 | Imported |  27/11/2023 |
| Rasagiline 1mg tablets | 42442211000001109 | Imported |  27/11/2023 |
| Rythmodan 100mg capsules | 42442411000001108 | Imported (Canada) |  27/11/2023 |
| Rifampicin 150mg capsules | 42442611000001106 | Imported |  27/11/2023 |
| Fluticasone 400microgram/unit dose nasal drops | 42490511000001100 | Imported (Spain) |  11/12/2023 |
| Dicycloverine 10mg/5ml oral solution | 42491411000001108 | Imported (United States) |  11/12/2023 |
| Propantheline bromide 15mg tablets | 21013011000001107 | Imported (United States) |  11/12/2023 |
| Propantheline bromide 15mg tablets | 42492011000001107 | Imported (Australia) |  11/12/2023 |
| Diazepam 2mg/5ml oral suspension sugar free | 42495311000001104 | Special Order |  11/12/2023 |
| Hydrogen peroxide 3% solution  | 42510811000001109 | Imported |  18/12/2023 |

**Invalidations**

This concept has been invalided. It has been authored under a new AMP, due to being historically added erroneously.

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Medicinal leeches(VMP not to be made invalid) | **VMP**N/A |
| **VMP SNOMED ID**34395111000001100 | **VMP SNOMED ID**N/A |
| **VMPP**1 leech (VMPP not to be made invalid) | **VMPP**N/A |
| **VMPP SNOMED ID**34395311000001103 | **VMPP SNOMED ID**N/A |
| **AMP**Medicinal leeches (Hirudo medicinalis) | **AMP**Medicinal leeches (Hirudo verbena) |
| **AMP SNOMED ID**34395711000001104 | **AMP SNOMED ID**42561511000001103 |
| **AMPP**1 leech | **AMPP**1 leech |
| **AMPP SNOMED ID**34395911000001102 | **AMPP SNOMED ID**42561611000001104 |

**Advance Notice of Invalidations**

The following concepts will be invalidated mid-January. They have been reauthored under new VMP’s.

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**N/A | **VMP**Levetiracetam 1g granules for oral solution sachets sugar free |
| **VMP SNOMED ID**N/A | **VMP SNOMED ID**42427011000001104 |
| **VMPP**N/A | **VMPP**60 sachets |
| **VMPP SNOMED ID**N/A | **VMPP SNOMED ID**42426211000001107 |
| **AMP**Levetiracetam 1g granules sachets sugar free (Neuraxpharm UK Ltd) | **AMP**Levetiracetam 1g granules for oral solution sachets sugar free (Neuraxpharm UK Ltd) |
| **AMP SNOMED ID**41541911000001100 | **AMP SNOMED ID**42426811000001108 |
| **AMPP**60 sachets | **AMPP**60 sachets |
| **AMPP SNOMED ID**41542011000001107 | **AMPP SNOMED ID**42426911000001103 |

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**N/A | **VMP**Levetiracetam 500mg granules for oral solution sachets sugar free |
| **VMP SNOMED ID**N/A | **VMP SNOMED ID**42427211000001109 |
| **VMPP**N/A | **VMPP**60 sachets |
| **VMPP SNOMED ID**N/A | **VMPP SNOMED ID**42426511000001105 |
| **AMP**Levetiracetam 500mg granules sachets sugar free (Neuraxpharm UK Ltd) | **AMP**Levetiracetam 500mg granules for oral solution sachets sugar free (Neuraxpharm UK Ltd) |
| **AMP SNOMED ID**41541711000001102 | **AMP SNOMED ID**42426611000001109 |
| **AMPP**60 sachets | **AMPP**60 sachets |
| **AMPP SNOMED ID**41541811000001105 | **AMPP SNOMED ID**42426711000001100 |

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**N/A | **VMP**Levetiracetam 250mg granules for oral solution sachets sugar free |
| **VMP SNOMED ID**N/A | **VMP SNOMED ID**42427111000001103 |
| **VMPP**N/A | **VMPP**60 sachets |
| **VMPP SNOMED ID**N/A | **VMPP SNOMED ID**42425811000001100 |
| **AMP**Levetiracetam 250mg granules sachets sugar free (Neuraxpharm UK Ltd) | **AMP**Levetiracetam 250mg granules for oral solution sachets sugar free (Neuraxpharm UK Ltd) |
| **AMP SNOMED ID**41541511000001107 | **AMP SNOMED ID**42426311000001104 |
| **AMPP**60 sachets | **AMPP**60 sachets |
| **AMPP SNOMED ID**41541611000001106 | **AMPP SNOMED ID**42426411000001106 |

The following concepts will be invalidated mid-January. The pack sizes were submitted erroneously.

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Metronidazole 500mg/100ml solution for infusion bottles (VMP not to be made invalid) | **VMP**N/A |
| **VMP SNOMED ID**34617211000001105 | **VMP SNOMED ID**N/A |
| **VMPP**10 bottle | **VMPP**20 bottle |
| **VMPP SNOMED ID**40752111000001103 | **VMPP SNOMED ID**36077011000001109 |
| **AMP**Metronidazole 500mg/100ml solution for infusion bottles (Kent Pharma (UK) Ltd)(AMP not to be made invalid) | **AMP**N/A |
| **AMP SNOMED ID**40752011000001104 | **AMP SNOMED ID**N/A |
| **AMPP**10 bottle | **AMPP**20 bottle |
| **AMPP SNOMED ID**40752311000001101 | **AMPP SNOMED ID**42428611000001105 |

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Ketamine 200mg/20ml solution for injection vials (VMP not to be made invalid) | **VMP**N/A |
| **VMP SNOMED ID**36036811000001102 | **VMP SNOMED ID**N/A |
| **VMPP**10 vial | **VMPP**1 vial |
| **VMPP SNOMED ID**40738011000001102 | **VMPP SNOMED ID**3988111000001101 |
| **AMP**Ketamine 200mg/20ml solution for injection vials (Kent Pharma (UK) Ltd) (AMP not to be made invalid) | **AMP**N/A |
| **AMP SNOMED ID**40738111000001101 | **AMP SNOMED ID**N/A |
| **AMPP**10 vial | **AMPP**1 vial |
| **AMPP SNOMED ID**40738311000001104 | **AMPP SNOMED ID**42428511000001106 |

dm+d Authoring Team